A Reproducible In-vivo Model of Lymphatic Malformation in Rats

Journal of Comparative Pathology

Volumn 145, Issue 4, 2011, Pages 390-398

  Sun, Y ^a   Jia, J ^b   Zhang, W ^b   Liu, B ^b   Zhang, Z ^a   Zhao, Y ^b  

^a Wuhan University   (China)

^b WUHAN UNIVERSITY   (China)

Author keywords

Adjuvant; Lymphatic malformation; Rat; VEGF C

Indexed keywords

ADJUVANT; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR 3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYST; ENDOTHELIUM; FEMALE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LYMPH VESSEL; LYMPHATIC SYSTEM DISEASE; MOUTH; NECK; NONHUMAN; PRIORITY JOURNAL; RAMAN SPECTROMETRY; RAT; TRANSMISSION ELECTRON MICROSCOPY;

ANIMALS; BIOLOGICAL MARKERS; BODY FLUIDS; DISEASE MODELS, ANIMAL; FEMALE; FREUND'S ADJUVANT; INJECTIONS; LYMPHATIC ABNORMALITIES; LYMPHOCELE; MOUTH; NECK; POLYSORBATES; RANDOM ALLOCATION; RATS; RATS, WISTAR; RECEPTORS, CELL SURFACE; RECOMBINANT PROTEINS; REPRODUCIBILITY OF RESULTS; SQUALENE; VASCULAR ENDOTHELIAL GROWTH FACTOR C; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3;

ANIMALIA; RATTUS;

EID: 80055025074     PISSN: 00219975     EISSN: 15323129     Source Type: Journal    
DOI: 10.1016/j.jcpa.2011.02.002     Document Type: Article

References (43)

1. Alving C.R. Design and selection of vaccine adjuvants: animal models and human trials. Vaccine 2002, 20:56-64.
2. Azizkhan R.G., Rutter M.J., Cotton R.T., Lim L.H., Cohen A.P., et al. Lymphatic malformations of the tongue base. Journal of Pediatric Surgery 2006, 41:1279-1284.
3. Blei F. Vascular anomalies: from bedside to bench and back again. Current Problems in Pediatric and Adolescent Health Care 2002, 32:72-93.
4. Blei F. Basic science and clinical aspects of vascular anomalies. Current Opinion in Pediatrics 2005, 17:501-509.
5. Boyce T.G., Hsu H.H., Sannella E.C., Coleman-Dockery S.D., Baylis E., et al. Safety and immunogenicity of adjuvanted and unadjuvanted subunit influenza vaccines administered intranasally to healthy adults. Vaccine 2000, 19:217-226.
6. Broker M., Beyer C. Adjuvants for human vaccines. Pharmazie in Unserer Zeit 2008, 37:42-51.
7. Castro E.C., Galambos C. Prox-1 and VEGFR3 antibodies are superior to D2-40 in identifying endothelial cells of lymphatic malformations - a proposal of a new immunohistochemical panel to differentiate lymphatic from other vascular malformations. Pediatric and Developmental Pathology 2009, 12:187-194.
8. Chen E.Y., Hostikka S.L., Oliaei S., Duke W., Schwartz S.M., et al. Similar histologic features and immunohistochemical staining in microcystic and macrocystic lymphatic malformations. Lymphatic Research and Biology 2009, 7:75-80.
9. Chen W.L., Zhang B., Wang J.G., Ye H.S., Zhang D.M., et al. Surgical excision of cervicofacial giant macrocystic lymphatic malformations in infants and children. International Journal of Pediatric Otorhinolaryngology 2009, 73:833-837.
10. Ch'ng S., Tan S.T. Pr08 lymphatic malformations and the molecular basis of lymphangiogenesis. Australian and New Zealand Journal of Surgery 2007, 77:63.
11. Cox J.C., Coulter A.R. Adjuvants - a classification and review of their modes of action. Vaccine 1997, 15:248-256.
12. Ezaki T., Kuwahara K., Morikawa S., Shimizu K., Sakaguchi N., et al. Production of two novel monoclonal antibodies that distinguish mouse lymphatic and blood vascular endothelial cells. Anatomy and Embryology 2006, 211:379-393.
13. Fendel S., Schrader B. Investigation of skin and skin lesions by NIR-FT-Raman spectroscopy. Fresenius' Journal of Analytical Chemistry 1998, 360:609-613.
14. Florez-Vargas A., Vargas S.O., Debelenko L.V., Perez-Atayde A.R., Archibald T., et al. Comparative analysis of D2-40 and LYVE-1 immunostaining in lymphatic malformations. Lymphology 2008, 41:103-110.
15. Giguere C.M., Bauman N.M., Smith R.J. New treatment options for lymphangioma in infants and children. Annals of Otology, Rhinology and Laryngology 2002, 111:1066-1075.
16. Gniadecka M., Philipsen P.A., Sigurdsson S., Wessel S., Nielsen O.F., et al. Melanoma diagnosis by Raman spectroscopy and neural networks: structure alterations in proteins and lipids in intact cancer tissue. Journal of Investigative Dermatology 2004, 122:443-449.
17. Greinwald J., Cohen A.P., Hemanackah S., Azizkhan R.G. Massive lymphatic malformations of the head, neck, and chest. Journal of Otolaryngology and Head and Neck Surgery 2008, 37:169-173.
18. Grimmer J.F., Mulliken J.B., Burrows P.E., Rahbar R. Radiofrequency ablation of microcystic lymphatic malformation in the oral cavity. Archives of Otolaryngology and Head and Neck Surgery 2006, 132:1251-1256.
19. Gupta R.K., Relyveld E.H., Lindblad E.B., Bizzini B., Ben-Efraim S., et al. Adjuvants - a balance between toxicity and adjuvanticity. Vaccine 1993, 11:293-306.
20. Jeltsch M., Kaipainen A., Joukov V., Meng X., Lakso M., et al. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science 1997, 276:1423-1425.
21. Junginger J., Rotting A., Staszyk C., Kramer K., Hewicker-Trautwein M. Identification of equine cutaneous lymphangioma by application of a lymphatic endothelial cell marker. Journal of Comparative Pathology 2010, 143:57-60.
22. Karavelioglu A., Temucin C.M., Tanyel F.C., Ciftci A.O., Senocak M.E., et al. Sclerotherapy with bleomycin does not adversely affect facial nerve function in children with cervicofacial cystic lymphatic malformation. Journal of Pediatric Surgery 2010, 45:1627-1632.
23. Kato S., Shimoda H., Ji R.C., Miura M. Lymphangiogenesis and expression of specific molecules as lymphatic endothelial cell markers. Anatomical Science International 2006, 81:71-83.
24. Krafft C. Bioanalytical applications of Raman spectroscopy. Analytical and Bioanalytical Chemistry 2004, 378:60-62.
25. Lei Z.M., Huang X.X., Sun Z.J., Zhang W.F., Zhao Y.F. Surgery of lymphatic malformations in oral and cervicofacial regions in children. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontics 2007, 104:338-344.
26. Liu Y.H., Wang Q.G., Jia J., Xiao S.F. Surgical treatment of lymphatic malformation located in head and neck in children. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2010, 45:38-41.
27. Makinen T., Veikkola T., Mustjoki S., Karpanen T., Catimel B., et al. Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3. EMBO Journal 2001, 20:4762-4773.
28. Mancardi S., Stanta G., Dusetti N., Bestagno M., Jussila L., et al. Lymphatic endothelial tumors induced by intraperitoneal injection of incomplete Freund's adjuvant. Experimental Cell Research 1999, 246:368-375.
29. Okazaki T., Iwatani S., Yanai T., Kobayashi H., Kato Y., et al. Treatment of lymphangioma in children: our experience of 128 cases. Journal of Pediatric Surgery 2007, 42:386-389.
30. Ott G., Barchfeld G.L., Chernoff D., Radhakrishnan R., van Hoogevest P., et al. MF59. Design and evaluation of a safe and potent adjuvant for human vaccines. Pharmaceutical Biotechnology 1995, 6:277-296.
31. Perkins J.A., Tempero R.M., Hannibal M.C., Manning S.C. Clinical outcomes in lymphocytopenic lymphatic malformation patients. Lymphatic Research and Biology 2007, 5:169-174.
32. Poldervaart M.T., Breugem C.C., Speleman L., Pasmans S. Treatment of lymphatic malformations with OK-432 (Picibanil): review of the literature. Journal of Craniofacial Surgery 2009, 20:1159-1162.
33. Raveh E., de Jong A.L., Taylor G.P., Forte V. Prognostic factors in the treatment of lymphatic malformations. Archives of Otolaryngology and Head and Neck Surgery 1997, 123:1061-1065.
34. Schultze V., D'Agosto V., Wack A., Novicki D., Zorn J., et al. Safety of MF59 adjuvant. Vaccine 2008, 26:3209-3222.
35. Short R.F., Shiels W.E., Sferra T.J., Nicol K.K., Schofield M., et al. Site-specific induction of lymphatic malformations in a rat model for image-guided therapy. Pediatric Radiology 2007, 37:530-534.
36. Sironi M., Conti A., Bernasconi S., Fra A.M., Pasqualini F., et al. Generation and characterization of a mouse lymphatic endothelial cell line. Cell and Tissue Research 2006, 325:91-100.
37. Small K., Ginsburg H., Greco M.A., Sarita-Reyes C., Kupchik G., et al. More than skin deep: a case of congenital lamellar ichthyosis, lymphatic malformation, and other abnormalities. Lymphatic Research and Biology 2008, 6:39-44.
38. Smith M.C., Zimmerman M.B., Burke D.K., Bauman N.M., Sato Y., et al. Efficacy and safety of OK-432 immunotherapy of lymphatic malformations. Laryngoscope 2009, 119:107-115.
39. Smith R.J. Lymphatic malformations. Lymphatic Research and Biology 2004, 2:25-31.
40. Testa J.E., Chrastina A., Oh P., Li Y., Witkiewicz H., et al. Immunotargeting and cloning of two CD34 variants exhibiting restricted expression in adult rat endothelia in vivo. American Journal of Physiology: Lung Cellular and Molecular Physiology 2009, 297:251-262.
41. Wolthuis R., van Aken M., Fountas K., Robinson J.S., Bruining H.A., et al. Determination of water concentration in brain tissue by Raman spectroscopy. Analytical Chemistry 2001, 73:3915-3920.
42. Zeng R.S., Liu X.Q., Wang A.X., Wang D.W., Wang J.N. Sequential treatment of giant lymphatic malformation of the tongue combined with severe oral and maxillofacial deformities. Journal of Oral and Maxillofacial Surgery 2008, 66:2364-2371.
43. Zhao F.Y. Diagnosis and treatment of lymphatic malformations. Zhonghua Kou Qiang Yi Xue Za Zhi 2008, 43:339-342.